Posters

The effects of 2% rebamipide ophthalmic suspension on ocular surface after cataract surgery

Poster Details

First Author: Y.Monden JAPAN

Co Author(s):    F. Hotokezaka   Y. Matsuo   S. Maeda   M. Kasaoka   R. Yamashita   R. Yamakawa     

Abstract Details

Purpose:

To evaluate the effects of 2% rebamipide ophthalmic suspension on ocular surface after cataract surgery.

Setting:

A prospective randomized study at Department of Ophthalmology, Kurume University Hospital.

Methods:

Sixty eyes of 49 patients who underwent phacoemulsification were randomized into rebamipide group and control group. Each group received topical bromfenac, betamethasone, and levofloxacin for 1 month postoperatively. Rebamipide group was also treated with rebamipide for postoperative 2 months. Patients with dry eye and/or diabetes were excluded from the study. Corneal and conjunctival fluorescein and lissamine green staining, tear breakup time (BUT), noninvasive BUT measured with the Oculus keratograph 5M, Schirmer test, corneal sensitivity test, conjunctival impression cytology, and subjective dry eye symptom assessment were performed before and 1 day, 1 week, 1 month, and 2 months after surgery.

Results:

Of 60 eyes, 55 eyes were eligible for analysis. Five eyes were excluded from the analysis due to additional treatment for complication, surgical procedure change for phacodonesis, or patient’s declination to participate after the surgery. Fluorescein staining score in rebamipide group was significantly lower at 1 week and 2 months after surgery than control group (p<0.01, Wilcoxon signed-rank test). Mean measurement of corneal sensitivity in rebamipide group was significantly higher at 1 week and 1 month after surgery than control group (1 week, p<0.05; 1 month, p<0.01; Wilcoxon signed-rank test).

Conclusions:

Two percent rebamipide ophthalmic suspension reduced corneal damage after cataract surgery.

Financial Disclosure:

None